Shanghai-based cell and gene therapy (CGT) specialist, Biosmelt Pharma, has entered into a partnership with Shenzhen Eureka Biotechnology Co., Ltd, a domestic CGT-focused Contract Development and Manufacturing Organization (CDMO) service provider.
Combining Expertise for Large-Scale Virus Vector Production
The collaboration aims to capitalize on Biosmelt’s GMP grade lentivirus vector suspension production process and Eureka’s lentivirus stable transfection cell line technology. Together, they will offer solutions for the large-scale production of virus vectors in the biologics and innovative drug sector, enhancing the safety, efficacy, and accessibility of CGT treatments. The partnership will also focus on product promotion and media resource collaboration. Financial details of the agreement have not been disclosed.- Flcube.com
